Literature DB >> 1751786

Is there a "point of no return" in progressive renal disease?

G Maschio, L Oldrizzi, C Rugiu.   

Abstract

The pathogenesis of progressive renal damage is most probably multifactorial. Whatever the mechanisms involved in renal disease progression, the existence of a "point of no return" has been hypothesized, that is, a stage of structural and functional damage beyond which progression of renal disease occurs independently of dietary measures and/or pharmacological treatment. In experimental animals, dietary protein and phosphate restriction is not fully successful in ameliorating the progression of functional deterioration if administered when renal injury is severe and long standing. Similarly, late treatment with various pharmacological agents (mainly antihypertensive drugs) is less effective than early administration of the same substances. A serum creatinine of 176 mumol/L seems a critical point discriminating the results of either dietary protein and phosphate restriction or antihypertensive treatment in patients with chronic renal disease. The protective effects of both dietary and nondietary intervention seem to be most effective when at least 50% of the residual renal mass is still functioning. The extent to which glomerular sclerosis, vascular hyalinosis, and interstitial fibrosis have already developed can probably blunt or avert the expected results of treatment. Some clinical tests may identify those patients who would benefit from measures such as the reduction in glomerular hemodynamic stress, the long-term inhibition of the renin-angiotensin system, and the aggressive treatment of systemic hypertension. The continuous search for a rational preventive treatment before the disease process has reached the "point of no return" will undoubtedly constitute a formidable task for the modern nephrologist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1751786     DOI: 10.1681/ASN.V24832

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  5 in total

Review 1.  Stage 5-CKD under nephrology care: to dialyze or not to dialyze, that is the question.

Authors:  Mario Pacilio; Roberto Minutolo; Carlo Garofalo; Maria Elena Liberti; Giuseppe Conte; Luca De Nicola
Journal:  J Nephrol       Date:  2015-11-19       Impact factor: 3.902

2.  Multicenter epidemiological study to assess the population of CKD patients in Greece: results from the PRESTAR study.

Authors:  Konstantinos Sombolos; Demitrios Tsakiris; John Boletis; Demetrios Vlahakos; Kostas C Siamopoulos; Vassilios Vargemezis; Pavlos Nikolaidis; Christos Iatrou; Eugene Dafnis; Konstantinos Xynos; Christos Argyropoulos
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

3.  Highlights from the 60th national meeting of the Italian Society of Nephrology: celebrating the role of the nephrologist.

Authors:  Luca De Nicola; Filippo Aucella; Giuliano Brunori
Journal:  J Nephrol       Date:  2020-12       Impact factor: 3.902

4.  The Assessment of the Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children.

Authors:  Agata Będzichowska; Katarzyna Jobs; Małgorzata Kloc; Anna Bujnowska; Bolesław Kalicki
Journal:  Biomark Insights       Date:  2021-04-20

Review 5.  Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?

Authors:  Luca De Nicola; Mario Cozzolino; Simonetta Genovesi; Loreto Gesualdo; Giuseppe Grandaliano; Roberto Pontremoli
Journal:  J Nephrol       Date:  2022-05-18       Impact factor: 4.393

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.